1-phenyl-3-(3,4,5-trimethoxyphenyl)-2-propen-1-one, also known as **piperine**, is the main alkaloid found in black pepper (Piper nigrum).
**Why is it important for research?**
Piperine has a wide range of potential pharmacological activities, making it an interesting subject for scientific research. Here are some key areas where it is being investigated:
* **Bioavailability Enhancement:** Piperine is known to increase the bioavailability of various drugs and nutrients. It works by inhibiting certain enzymes in the gut that break down these substances, leading to increased absorption and efficacy. This has implications for drug delivery and the development of new therapeutic strategies.
* **Antioxidant and Anti-Inflammatory Effects:** Piperine exhibits potent antioxidant properties, scavenging free radicals and reducing oxidative stress. It also possesses anti-inflammatory effects, potentially mediating the inflammatory response in various diseases. This makes it a promising candidate for the treatment of inflammatory conditions like arthritis and inflammatory bowel disease.
* **Neuroprotective Activity:** Studies suggest that piperine may protect nerve cells from damage and promote neuronal survival. This potential neuroprotective effect is being investigated for its potential in treating neurodegenerative diseases like Alzheimer's and Parkinson's.
* **Anti-Cancer Properties:** Several in vitro and in vivo studies have indicated that piperine exhibits anti-cancer activity against various types of cancer cells. It can induce apoptosis (programmed cell death) and inhibit the growth and spread of cancer cells.
* **Other Potential Benefits:** Piperine has been associated with other potential benefits, including:
* Improved glucose metabolism and blood sugar control
* Weight management
* Anti-microbial activity
* Liver protection
* Cardiovascular health
**Current Research:**
Extensive research is ongoing to investigate the mechanisms of action of piperine and its potential applications in various medical fields. Studies focus on:
* Identifying the specific molecular targets of piperine and how it interacts with them.
* Developing new formulations and delivery systems for efficient and targeted drug delivery.
* Exploring the safety and efficacy of piperine in human clinical trials.
**Important Note:** While piperine shows promise in preclinical research, further studies are needed to confirm its effectiveness and safety in humans. It is essential to consult with a healthcare professional before using any dietary supplements containing piperine, as they may interact with medications or have other adverse effects.
ID Source | ID |
---|---|
PubMed CID | 262540 |
CHEMBL ID | 1880298 |
SCHEMBL ID | 11796150 |
Synonym |
---|
smr002048877 |
CHEMBL1880298 |
SCHEMBL11796150 |
AKOS030239682 |
Q27163814 |
3,4,5-trimethoxychalcone |
Class | Description |
---|---|
chalcones | A ketone that is 1,3-diphenylpropenone (benzylideneacetophenone), ArCH=CH(=O)Ar, and its derivatives formed by substitution. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Nrf2 | Homo sapiens (human) | Potency | 5.0119 | 0.0920 | 8.2222 | 23.1093 | AID624171 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 28.1838 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
TDP1 protein | Homo sapiens (human) | Potency | 7.0022 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Smad3 | Homo sapiens (human) | Potency | 12.3318 | 0.0052 | 7.8098 | 29.0929 | AID588855; AID720534; AID720536; AID720537 |
IDH1 | Homo sapiens (human) | Potency | 10.3225 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 35.4813 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | Potency | 15.8489 | 0.0580 | 10.6949 | 26.6086 | AID602310 |
Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 17.7828 | 6.3096 | 60.2008 | 112.2020 | AID720709 |
Alpha-synuclein | Homo sapiens (human) | Potency | 22.3872 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 14.1254 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745849 | Viability Counterscreen for CMV-Luciferase Assay of Inhibitors of ATXN expression | |||
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID1745846 | Firefly Luciferase Counterscreen for Inhibitors of ATXN expression | |||
AID1745850 | Viability Counterscreen for Confirmatory qHTS for Inhibitors of ATXN expression | |||
AID1745847 | CMV-Luciferase Counterscreen for Inhibitors of ATXN expression | |||
AID1745848 | Confirmatory qHTS for Inhibitors of ATXN expression | |||
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 2 (33.33) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.38) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |